CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenues:
Total revenues	$ 29,443	$ 28,754	$ 27,116
Costs and expenses:
Cost of goods sold	6,234	6,251	6,498
Research and development expenses	5,799	5,907	5,718
Acquired in-process research and development expenses	1,024	4,663	1,155
In-process research and development impairments	590	4,180	50
Selling, general and administrative expenses	5,774	6,091	6,090
Total costs and expenses	19,421	27,092	19,511
Operating income	10,022	1,662	7,605
Interest expense	1,024	977	944
Other (income) expense, net	(798)	(6)	(198)
Income before income taxes	9,796	690	6,859
Income tax (benefit) expense	1,286	211	1,247
Net income	8,510	480	5,613
Net loss attributable to noncontrolling interest	0	0	(52)
Net income attributable to Gilead	$ 8,510	$ 480	$ 5,665
Basic earnings per share attributable to Gilead (in dollars per share)	$ 6.84	$ 0.38	$ 4.54
Diluted earnings per share attributable to Gilead (in dollars per share)	$ 6.78	$ 0.38	$ 4.50
Shares used in basic earnings per share attributable to Gilead calculation (in shares)	1,244	1,247	1,248
Shares used in diluted earnings per share attributable to Gilead calculation (in shares)	1,255	1,255	1,258
Product sales
Revenues:
Total revenues	$ 28,915	$ 28,610	$ 26,934
Royalty, contract and other revenues
Revenues:
Total revenues	$ 527	$ 144	$ 182

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Operating Activities:
Net income	$ 8,510	$ 480	$ 5,613
Adjustments to reconcile Net income to Net cash provided by operating activities:
Depreciation expense	370	381	354
Amortization expense	2,390	2,386	2,339
Stock-based compensation expense	894	835	766
Deferred income taxes	160	(1,844)	(962)
Net (gain) loss from equity securities	(451)	274	167
Acquired in-process research and development expenses	1,024	4,663	1,155
In-process research and development impairments	590	4,180	50
Other, net	480	353	826
Changes in operating assets and liabilities:
Accounts receivable, net	(367)	139	157
Inventories	(1,036)	(426)	(842)
Prepaid expenses and other	(311)	(259)	39
Accounts payable	(132)	290	(347)
Income tax assets and liabilities, net	(2,108)	(732)	(1,768)
Accrued and other liabilities	6	108	458
Net cash provided by operating activities	10,019	10,828	8,006
Investing Activities:
Purchases of marketable debt securities	(3,939)	(244)	(1,930)
Proceeds from sales of marketable debt securities	854	2,265	510
Proceeds from maturities of marketable debt securities	55	327	1,334
Acquisitions, including in-process research and development, net of cash acquired	(1,070)	(4,840)	(1,152)
Purchases of equity securities	(133)	(492)	(442)
Purchases of property, plant and equipment	(563)	(523)	(585)
Other investing activities, net	2	58	(1)
Net cash used in investing activities	(4,793)	(3,449)	(2,265)
Financing Activities:
Proceeds from debt financing, net of issuance costs	0	3,464	1,980
Proceeds from issuances of common stock	408	422	232
Repurchases of common stock under repurchase programs	(1,922)	(1,150)	(1,000)
Repayments of debt and other obligations	(1,788)	(1,970)	(2,250)
Payments of dividends	(4,003)	(3,918)	(3,809)
Other financing activities, net	(440)	(281)	(279)
Net cash used in financing activities	(7,745)	(3,433)	(5,125)
Effect of exchange rate changes on cash and cash equivalents	92	(40)	57
Net change in cash and cash equivalents	(2,428)	3,906	673
Cash and cash equivalents at beginning of period	9,991	6,085	5,412
Cash and cash equivalents at end of period	$ 7,564	$ 9,991	$ 6,085

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 7,564	$ 9,991
Short-term marketable debt securities	68	0
Accounts receivable, net	4,913	4,420
Inventories	1,774	1,710
Prepaid and other current assets	4,024	3,052
Total current assets	18,342	19,173
Property, plant and equipment, net	5,606	5,414
Long-term marketable debt securities	2,974	0
Intangible assets, net	16,978	19,948
Goodwill	8,314	8,314
Deferred tax assets	1,964	2,378
Other long-term assets	4,845	3,769
Total assets	59,023	58,995
Current liabilities:
Accounts payable	715	833
Accrued rebates	4,337	3,892
Current portion of long-term debt, net	2,807	1,815
Other current liabilities	3,953	5,464
Total current liabilities	11,813	12,004
Long-term debt, net	22,129	24,896
Long-term income taxes payable	896	830
Deferred tax liabilities	402	724
Other long-term liabilities	1,165	1,295
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding	0	0
Common stock, par value $0.001 per share; 5,600 authorized; 1,241 and 1,246 shares issued and outstanding, respectively	1	1
Additional paid-in capital	8,932	7,700
Accumulated other comprehensive income	39	132
Retained earnings	13,730	11,497
Total Gilead stockholders’ equity	22,703	19,330
Noncontrolling interest	(84)	(84)
Total stockholders’ equity	22,618	19,246
Total liabilities and stockholders’ equity	$ 59,023	$ 58,995